<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03021265</url>
  </required_header>
  <id_info>
    <org_study_id>1348.6</org_study_id>
    <nct_id>NCT03021265</nct_id>
  </id_info>
  <brief_title>To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension</brief_title>
  <official_title>The Special Drug Use-results Survey on Long-term Use of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed Dose Combination Tablets in Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate real-world safety, effectiveness and appropriate use of Micatrio®
      Combination Tablets treatment in patients with hypertension
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-interventional study based on newly collected data. The study will consist of a baseline
      visit and follow-up visits at Week 4, 8, 12, 24, 36 and 52 for patients who have newly
      initiated Micatrio® Combination Tablets. The patients will be followed up until
      discontinuation of Micatrio® Combination Tablets treatment or the end of study.

      All patients administrated Micatrio® Combination Tablets after the launch at the sites
      contracted with the sponsor will be registered.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 20, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The frequency of patients with any suspected adverse drug reactions</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>The frequency of patients with any suspected adverse drug reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood pressure at Week 52</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Change from baseline in blood pressure at Week 52</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">676</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>T80/A5/H12.5 FDC</arm_group_label>
    <description>Patients with hypertension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T80/A5/H12.5 FDC</intervention_name>
    <description>Drug</description>
    <arm_group_label>T80/A5/H12.5 FDC</arm_group_label>
    <other_name>MICATRIO</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        500
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients who are prescribed with Micatrio® Combination Tablets by the discretion of
             investigators based on the Japanese package insert

          -  Patients who have never been treated with Micatrio® Combination Tablets before
             enrolment

        Exclusion criteria:

        Patients who are participating/planned to participate in a clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rie Ikeda</last_name>
    <role>Study Chair</role>
    <affiliation>+81364172200 zzCDMJP_PV_PMS@boehringer-ingelheim.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nippon Boehringer Ingelheim Co., Ltd</name>
      <address>
        <city>Tokyo</city>
        <zip>4570047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2017</study_first_submitted>
  <study_first_submitted_qc>January 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

